These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23217055)

  • 21. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.
    Hu X; Dong R; Huang S; Zeng Y; Zhan W; Gao X; Tian D; Peng J; Xu J; Wang T; Zhang Y; Wang X; Zhang X; Liu J; Guang B; Yang T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170422. PubMed ID: 37052498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Vancomycin as Secondary Prophylaxis for
    Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
    Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of adenosine A₂A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice.
    Warren CA; Calabrese GM; Li Y; Pawlowski SW; Figler RA; Rieger J; Ernst PB; Linden J; Guerrant RL
    BMC Infect Dis; 2012 Jan; 12():13. PubMed ID: 22264229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
    Moore JH; van Opstal E; Kolling GL; Shin JH; Bogatcheva E; Nikonenko B; Einck L; Phipps AJ; Guerrant RL; Protopopova M; Warren CA
    J Antimicrob Chemother; 2016 May; 71(5):1300-6. PubMed ID: 26832756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Individualized treatment strategies for Clostridium difficile infections].
    Solbach P; Dersch P; Bachmann O
    Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new strategy for the prevention of Clostridium difficile infection.
    Howerton A; Patra M; Abel-Santos E
    J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
    Bassis CM; Theriot CM; Young VB
    Antimicrob Agents Chemother; 2014 May; 58(5):2767-74. PubMed ID: 24590475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
    Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
    Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary study of bowel rest strategy in the management of Clostridioides difficile infection.
    Sugimoto H; Yoshihara A; Yamamoto T; Sugimoto K
    Sci Rep; 2020 Dec; 10(1):22061. PubMed ID: 33328505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation.
    Sharma AK; Linden J; Kron IL; Laubach VE
    Respir Res; 2009 Jun; 10(1):58. PubMed ID: 19558673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
    Knight EM; Schiller DS; Fulman MK; Rastogi R
    J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of adenosine A(2B) receptors in Clostridium difficile intoxication and infection.
    Warren CA; Li Y; Calabrese GM; Freire RS; Zaja-Milatovic S; van Opstal E; Figler RA; Linden J; Guerrant RL
    Infect Immun; 2012 Dec; 80(12):4463-73. PubMed ID: 23045479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of oral vancomycin treatment duration on rate of
    Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
    Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent
    Chang LL; Allegretti J; Skinner AM; Dubberke ER
    N Engl J Med; 2023 Feb; 388(7):654-656. PubMed ID: 36791167
    [No Abstract]   [Full Text] [Related]  

  • 40. Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI).
    Manthey CF; Dranova D; Christner M; Drolz A; Kluge S; Lohse AW; Fuhrmann V
    Crit Care; 2019 Dec; 23(1):399. PubMed ID: 31815650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.